Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
NCT ID: NCT05645744
Last Updated: 2024-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
3 participants
OBSERVATIONAL
2021-09-29
2024-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
NCT04488354
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
NCT03436771
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671
Long-term Follow-up Study of Patients Receiving CAR-T Cells
NCT03375619
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
NCT06210243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prior MB-102 CAR-T cell investigational product.
Patients previously treated with MB-102 CAR-T cell investigational product.
Prior MB-102 CAR-T cell investigational product.
No investigational product will be administered.
Prior MB-106 CAR-T cell investigational product.
Patients previously treated with MB-106 CAR-T cell investigational product.
Prior MB-106 CAR-T cell investigational product.
No investigational product will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prior MB-102 CAR-T cell investigational product.
No investigational product will be administered.
Prior MB-106 CAR-T cell investigational product.
No investigational product will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has provided signed and dated informed consent.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mustang Bio
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Dezube, M.D.
Role: STUDY_DIRECTOR
Mustang Bio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Rochester Medical Center
Rochester, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MB100-OBS-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.